Raymond James & Associates Arcutis Biotherapeutics, Inc. Transaction History
Raymond James & Associates
- $146 Billion
- Q1 2024
A detailed history of Raymond James & Associates transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 41,442 shares of ARQT stock, worth $434,726. This represents 0.0% of its overall portfolio holdings.
Number of Shares
41,442Holding current value
$434,726% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ARQT
# of Institutions
172Shares Held
126MCall Options Held
498KPut Options Held
1.64M-
Jennison Associates LLC12.2MShares$128 Million0.08% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$92.2 Million4.57% of portfolio
-
State Street Corp Boston, MA8.78MShares$92.1 Million0.0% of portfolio
-
Suvretta Capital Management, LLC New York, NY7.88MShares$82.6 Million3.34% of portfolio
-
Rubric Capital Management LP New York, NY7.51MShares$78.8 Million2.54% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $631M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...